



Despoina Pantazi, Chemist, MSc, PhD

Teaching Staff in Laboratory of Biochemistry & Clinical Chemistry,
Department of Chemistry, University of Ioannina (UOI), 45110, Greece
Partner of the Atherothrombosis Research Centre (ARC) of the UOI
E-mail: dpantazi@uoi.gr, Tel: (+30) 26510-08378 & (+30) 6977873037
www.linkedin.com/in/despoina-pantazi-639662232

- **Work experience**

9/2022: Short visit at the Department of Endocrinology and Nutrition, August Pi i Sunyer Biomedical Research Institute (IDIBARS), Hospital Clinic of Barcelona, Spain, in the frame of the program Erasmus+ Staff Mobility (code 83098)

10/2019: Short visit for training in laboratory techniques at Cardiovascular Program-ICCC, IR-Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona (UAB) (Professor Lina Badimon), Barcelona, Spain, in the frame of the program Erasmus+ Staff Mobility (code 82484)

1/2017 – present: Participation in several protocols in the Lab of Biochemistry, Dep of Chemistry, UOI, Greece

6/2012-6/2015: Career break (Maternity leave)

30/6/2014 – present: Laboratory Teaching Staff (permanent position) in Laboratory of Biochemistry & Clinical Chemistry, Department of Chemistry, UOI, Greece

20/03/2007 – 30/6/2014: Staff as a Chemist with an indefinite term contract in UOI, Greece

10/4/2000 – 31/12/2008 & 24/1/2022 – 28/11/2023: Experience in 14 research programs

- **Teaching Activities - Supervision**

Lessons: Intr to Clin Biochemistry, Clin Chemistry, Lab of Clin Chemistry (4th y), Lab of Biochemistry (3rd y)

Supervision: Master Thesis and Thesis of undergraduate students

Member of a three-member examination committee for a postgraduate diploma

- **Qualifications – Studies**

Post-doc Research in Lab of Biochem. Dep. of Chemistry, UOI, Greece (10/2009-9/2010, 744^A/8-5-09),

Doctoral Thesis Department of Chemistry, UOI, Greece (2008), **Master's Degree** in Chemistry of Biomolecular and Biochemistry, Department of Chemistry, UOI, Greece (2003), **Degree in Chemistry**, Department of Chemistry, UOI, Greece (2000)

Languages: Greek (mother tongue), English, and Spanish (Basic Level)

- **Academic prizes – Scholarships**

12/2020: Awardee of a prestigious Academy of Athens award (Academy of Sciences), Greece, **10/2020:** 1st Award in the 8th Panhellenic Congress of ISETAT, **9/2017:** Best Poster Award in the 5th Panhellenic Congress of ISETAT (Institute for the Study and Education on Thrombosis and Antithrombosis Therapy), Athens, Greece, **10/2006:** Scholarship from FEBS for the poster presentation in the conference FEBS Special Meeting European Lipidomics Initiative; New Concepts in Lipidology: from Lipidomics to disease. Noordwijkerhooft, Netherlands, **4/2004:** Second prize for poster presentation at the conference 9th State of the Art Interdisciplinary Review of Course, Athens, Greece, **11/2003-11/2005:** Scholarship "Heraclitus" from the Greek Ministry of Education, **9/1995:** Scholarship from the Greek State Scholarship Foundation "IKY"

- **Member of Scientific Societies**

- European Atherosclerosis Society (EAS) (Membership Number 60739847)

- European Society of Cardiology (ESC) (ESC ID: 1217561)/ (Council of CardioOncology, Reg until 19/9/2023 and on WG on Thrombosis Member, until 2/4/24)

- EMLTD (European and Mediterranean League Against Thrombotic Diseases, regular member)

- EHA (European Hematology Association) (Guest Member of EHA, ID: 5644729)

- ESMO (ID: 5644729)

- Hellenic Atherosclerosis Society (HAS, Regular Member)

- Institute for the Study and Education on Thrombosis and Antithrombotic Therapy (ISETAT). *Member of the Steering Committee of ISETAT (1/10/2022-30/9/2024)*

- Hellenic Union of Chemists (Reg Number 11050)

International Conferences: 30; National Conferences: 40; Book Chapters: 8 (7 in an open Greek e-book, 1 in an International Book)

- **Selected Publications**

1. Pantazi D., Ntemou N., Brentas A., Alivertis D., Skobridis K., Tselepis A.D. **Molecular requirements for the expression of antiplatelet effects by synthetic structural optimized analogues of the anticancer drugs imatinib and nilotinib.** *Drug Design, Development and Therapy*, 2019; 13:4225–4238, <http://doi.org/10.2147/DDDT.S21190>.

2. Sidiropoulou S, Papadaki S, Tsouka AN, Koutsaliaris IK, Chantzichristos VG, **Pantazi D,** Paschopoulos ME, Hansson KM, Tselepis AD (2021) **The Effect of Platelet-Rich Plasma on Endothelial Progenitor Cell Functionality.** *Angiology* 72:776-786. <https://doi.org/10.1177/0003319721998895>.

3. Pantazi D, Tselepis A.D. **Cardiovascular toxic effects of antitumor agents: Pathogenetic mechanisms.** *Thromb Res.* 2022;213:S95-S102. <https://doi.org/10.1016/j.thromres.2021.12.017>.

4. Tzimas P, Lefkou E, Karakosta A, Argyrou S, Papapetrou E, **Pantazi D.,** Tselepis A, Van Dreden P, Stratigopoulou P, Gerotziapas GT, Glantzounis G. **Perioperative coagulation profile in major liver resection for cancer: a prospective observational study.** *Thromb Haemost.* 2022, 122 (10), 1662-1672

5. Pantazi D., Tellis C, Tselepis AD (2022) **Oxidized phospholipids and lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) in atherosclerotic cardiovascular disease: An update.** *Biofactors* 48:1257-1270. <https://doi.org/10.1002/biof.1890> (after invitation).

6. Kosma A., **Pantazi D.,** Voulgari P, Ntemou N., Brentas A., Alivertis D., Siskos M.G., Tselepis A.D., Skobridis K. **Expressing enhanced inhibitory effects toward arachidonic acid induced platelet activation: Design, synthesis, DFT calculations and in vitro evaluation of imatinib analogues.** *ChemistrySelect* 2023, 8, e202200405.